1. Home
  2. News
  3. News
  4. Nasal spray new drug AD17002-AI applied to allergic rhinitis treatment in phase Ib/IIa human trial has been completed. The CSR(clinical study report) will be released in December.

Nasal spray new drug AD17002-AI applied to allergic rhinitis treatment in phase Ib/IIa human trial has been completed. The CSR(clinical study report) will be released in December.

Nasal spray new drug AD17002-AI applied to allergic rhinitis treatment in phase Ib/IIa human trial has been completed. The CSR(clinical study report) will be released in December.
2020-07-11
Back
繁體中文
English
简体中文
This site uses cookies to collect the necessary user browsing behavior so that we can provide you with a better browsing experience. Browse this site, which means you agree with "online privacy declaration."